Kyowa Kirin Co., Ltd. (TYO:4151)
2,398.00
+9.50 (0.40%)
Jun 16, 2026, 11:30 AM JST
Kyowa Kirin Employees
Kyowa Kirin had 5,161 employees as of December 31, 2025. The number of employees decreased by 508 or -8.96% compared to the previous year.
Employees
5,161
Change (1Y)
-508
Growth (1Y)
-8.96%
Revenue / Employee
98.93M JPY
Profits / Employee
14.13M JPY
Market Cap
1.25T
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 5,161 | -508 | -8.96% |
| Dec 31, 2024 | 5,669 | -305 | -5.11% |
| Dec 31, 2023 | 5,974 | - | - |
| Dec 31, 2021 | 5,752 | 329 | 6.07% |
| Dec 31, 2020 | 5,423 | 156 | 2.96% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Otsuka Holdings | 37,758 |
| Daiichi Sankyo Company | 19,765 |
| Astellas Pharma | 13,643 |
| Chugai Pharmaceutical | 5,104 |
| Ono Pharmaceutical | 4,287 |
| Santen Pharmaceutical | 3,849 |
| JCR Pharmaceuticals | 987 |
| Perseus Proteomics | 32 |
Kyowa Kirin News
- 5 days ago - Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL - GlobeNewsWire
- 4 weeks ago - Kura, Kyowa Kirin to present updated frontline data from Phase 1 KOMET-007 trial - TheFly
- 5 weeks ago - Kyowa Kirin Quarterly report: Q1 2026 - Filings
- 5 weeks ago - Kyowa Kirin Slides: Q1 2026 - Filings
- 3 months ago - Kyowa Kirin downgraded to Sell from Buy at Citi - TheFly
- 3 months ago - Kyowa Kirin downgraded to Underweight from Equal Weight at Morgan Stanley - TheFly
- 3 months ago - Kyowa Kirin downgraded to Neutral from Outperform at SMBC Nikko - TheFly
- 3 months ago - Kyowa Kirin downgraded to Underweight from Neutral at JPMorgan - TheFly